WebPurpose of review: The therapeutic use of anti-PD-1/PD-L1 antibodies (nivolumab, pembrolizumab) is rapidly increasing. Given their mechanism of action that triggers T … WebJan 13, 2024 · Gynecol Oncol 2016; 140:409. Huang GS, Chiu LG, Gebb JS, et al. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. ... Wright JD. Uterine carcinosarcoma. Curr Opin Oncol 2011; 23:531. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of …
Current Opinion in Oncology - Resurchify
WebApr 26, 2024 · Laboratory professionals are in an ideal situation to identify CBC and peripheral blood smear findings that raise the possibility of a hematolymphoid … Web2 days ago · Aims & scope. Current Treatment Options in Oncology offers in-depth review articles contributed by international experts on the most significant developments in the field. By providing clear, insightful, balanced review articles that emphasize recently published papers of major importance, the journal elucidates current and emerging … cshhc-sus-m6-20
Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults ...
WebMar 30, 2024 · Curr Opin Oncol 2016; 28:314. Tap WD, Villalobos VM, Cote GM, et al. Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. J Clin Oncol 2024; 38:1693. Peterse EFP, van den Akker BEWM, Niessen B, et al. NAD Synthesis Pathway Interference Is a Viable … WebMar 14, 2024 · ※1 Kourie HR, Klastersky JA. Side-effects of checkpoint inhibitor-based combination therapy. Curr Opin Oncol. 2016;28(4): 306-13. Using in-house modality platforms to create new immuno-oncology treatment methods. Astellas is committed to pursuing multiple R&D approaches that address the entire cancer-immunity cycle. WebCurrent Opinion in Oncology: July 2016 - Volume 28 - Issue 4 - p 359-366. doi: 10.1097/CCO.0000000000000299. Buy; Metrics Abstract. Purpose of review . ... Current … eagers automotive asx announcements